Investor Presentaiton
Citadel Group | Investor Presentation | 13
◇ Underlying Financial performance
For personal use only
Strong growth in Underlying Revenue and
Underlying EBITDA
$m
Total Revenue
Gross Profit
Gross Profit Margin
EBITDA
EBITDA Margin
Depreciation & Amortisation
EBIT
Finance Costs
NPBT
Tax Expense
NPAT from Continuing Operations
FY20 Pro
Forma*
FY20
FY19
Change
150.9
128.4
99.2
29.4%
72.2
55.8
45.0
24.0%
47.8%
43.5%
45.4%
38.4
29.2
23.3
25.3%
25.4%
22.7%
23.5%
12.2
8.0
52.5%
Underlying Revenue $128.4 million
> Revenue from Enterprise, Health and Professional Services in line with expectations -
no material impact from COVID-19
- 66.5% growth in Citadel-IX™, 35.3% growth in Enterprise a highlight
> Technology revenues were impacted in Q4 from reduced university spend, down 11%
on PCP as a result of COVID-19
> Wellbeing contributed revenue $7.6m, gross profit $5.3m and EBITDA $3.5m. GBP in
line with expectations, AUD conversion impacted by FX movements
Gross margin of 43.5%
17.0
15.3
11.1%
> Margin excluding Noventus of 48.8% - improvement on PCP
2.1
1.0
110.0%
14.9
14.3
4.2%
3.3
3.4
(2.9%)
11.6
10.9
6.4%
> Gross margin improves to 47.8% on a pro forma basis and is expected to improve as
software growth continues
Underlying EBITDA $29.2 million
> SG&A increased from $21.8m to $26.5m, with Wellbeing contributing $2.1m and
investment in growing in-house capabilities through internal re-structuring and
strategic hires and a full year contribution from Gruden and Noventus acquisitions
*
Refer Appendices for Pro Forma calculationView entire presentation